Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Feature|Podcasts|April 14, 2025
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
Author(s)Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Advertisement
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural imagery, and prioritize sites with diverse patient demographics. She also explains how they've enhanced investigator diversity through educational sessions and multilingual toolkits, and how Takeda aims to expand these efforts globally.
Advertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
Viatris Acquires Pacira BioSciences for $1.65 Billion
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
5